Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis

American Journal of Ophthalmology

Volumn 125, Issue 3, 1998, Pages 292-300

  Zegans, Michael E ^a,b   Walton, R Christopher ^d   Holland, Gary N ^e   O'Donnell, James J ^b   Jacobson, Mark A ^b,c   Margolis, Todd P ^a,b,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Francis I Proctor Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYCLOPENTOLATE; FOSCARNET; GANCICLOVIR; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PREDNISOLONE ACETATE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINITIS; TOPICAL DRUG ADMINISTRATION; VIRUS REACTIVATION; VITREOUS DISEASE;

EID: 18144436054     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(99)80134-2     Document Type: Article

References (24)

1. 1. Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996;114:821-827.
2. + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993;115: 575-582.
3. 3. Holland GN, Pepose JS, Pettit TH, Gottleib MS, Yee RD, Foos RY. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 1983;90:859-871.
4. 4. Palestine AG, Rodrigues MM, Macher AM, et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984;91:1092-1099.
5. 5. Elkins BS, Holland GN, Opremcak EM, et al. Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immunocompromised patients. Ophthalmology 1994;101: 499-507.
6. 6. Berger BB, Weinberg RS, Tessler HH, Wyhinny GJ, Vygantas CM. Bilateral cytomegalovirus panuveitis after high-dose corticosteroid therapy. Am J Ophthalmol 1979;88:1020-1025.
7. 7. Pollard RB, Egbert PR, Gallagher JG, Merigan TC. Cytomegalovirus retinitis in immunosuppressed hosts. Ann Intern Med 1980;93:655-664.
8. 8. Murray HW, Knox DL, Green WR, Susel RM. Cytomegalovirus retinitis in adults. Am J Med 1977;63:574-584.
9. 9. Chumbley LC, Robertson DM, Smith TF, Campbell RJ. Adult cytomegalovirus inclusion retino-uveitis. Am J Ophthalmol 1975;80:807-816.
10. 10. Porter R. Acute necrotizing retinitis in a patient receiving immunosuppressive therapy. Br J Ophthalmol 1972;56:555-558.
11. 11. Mills RW. Ocular cytomegalovirus inclusion disease in the adult. Trans Ophthalmol Soc UK 1977;97:501-505.
12. 12. Egbert PR, Pollard RB, Gallagher JG, Merigan TC. Cytomegalovirus retinitis in immunosuppressed hosts. Ann Intern Med 1980;93:664-670.
13. 13. Aaberg TM, Cesarz TJ, Rytel W. Correlation of virology and clinical course of cytomegalovirus retinitis. Am J Ophthalmol 1972;74:407-415.
14. 14. Decks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. JAMA 1997;277:145-153.
15. 15. Jacobson M, Zegans M, Pavan P, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-1445.
16. 16. Phillips P, Zala C, Rouleau D, Montaner JSG. Mycobacterial lymphadenitis: can highly active antiretroviral therapy (HAART) unmask subclinical infection? In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1996. Infectious Diseases Society of America, Alexandria, VA, 1996:129.
17. 17. Race E, Adelson-Mitty J, Barlam T, Japour A. Focal Inflammatory lymphadenitis (FIL) and fever following initiation of protease inhibitor (PRI) in patients with advanced HIV-1 disease. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1996. Infectious Diseases Society of America, Alexandria, VA, 1996:129.
18. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-149.
19. 19. Lefrancois L, Puddington L. Extrathymic intestinal T-cell development: virtual reality? Immunol Today 1995;16:16-21.
20. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-540.
21. + T-cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
22. 22. Pepose JS, Newman C, Bach MC, et al. Pathologic features of cytomegalovirus retinopathy after treatment with the antiviral agent ganciclovir. Ophthalmology 1987;94:414-424.
23. 23. Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997; 124:199-205.
24. 24. Whitcup SM, Fortin E, Nussenblatt RB, Polis MA, Muccioli C, Belfort R Jr. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA 1997;19: 1519-1520.